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Data from the Western Cape Province of South Africa (SA) show that 
among women seeking treatment for substance abuse, the proportion 
of heroin-related admissions increased significantly from 4.8% in 
2000 to 5.6% in 2013.[1] With increasing use of the heroin-based drug 
nyaope in Gauteng Province and other parts of SA, it is expected 
that more women are becoming in need of treatment for heroin 
dependence throughout the country.[2,3] Although lacking in detail, 
the South African National Drug Master Plan (2013 - 2017) listed 
women with substance use disorders as a priority area for attention 
and action by national and provincial departments.[4]
Epidemiological research shows that women with substance use 
disorders often have a different course of illness and treatment needs 
to men.[5] Telescoping, the term used to describe rapid progression 
from use of first substance to substance dependence and first 
admission to treatment, is often seen in women with opioid, cannabis 
and alcohol dependence.[6,7] Despite using less of the substance for 
a shorter period of time, women therefore typically present with 
a more severe clinical profile than men. Women also tend to have 
more psychiatric and non-psychiatric comorbidities and more severe 
social difficulties.[5] Furthermore, the dual diagnosis of mental illness 
and substance use disorder infers a poorer prognosis.[8-10] Women 
with substance dependence are more likely than those without to 
contract HIV, experience intimate partner violence and engage in 
sex work. [8,11,12] Added to these harms, women also face significant 
barriers to accessing treatment.[13,14]
In an SA context, awareness of treatment options and geographical 
access to treatment were notable barriers to treatment for women 
in the Western Cape.[14] Qualitative data from Australia highlighted 
social stigma, concerns about child care and the perceived economic 
and time costs of treatment as a few of the deterrents preventing 
women from accessing treatment.[13] The United Nations General 
Assembly Special Session on the World Drug Problem in 2016 
emphasised the specific needs of women. The outcome document 
calls for a gender-sensitive drug policy that eliminates all forms of 
discrimination against women and a policy that takes into account 
the specific needs and circumstances they face.[15]
Gender-sensitive treatment services have been evaluated in 
developed countries. Studies suggest that women in women-only 
treatment programmes have better outcomes than those in mixed-
gender treatment programmes.[16-18] Additionally, randomised con-
trolled trials have demonstrated the efficacy of gender-specific 
treatment services that cater to the specific needs of subpopulations 
of women with substance use disorders.[19-22] These include women 
with children, women with comorbid psychiatric disorders, and 
women in the criminal justice system.
Men certainly also suffer the severe harms associated with substance 
abuse. However, despite our knowledge of the specific vulnerabilities 
of women with substance use disorders, drug policy and treatment 
services, including those in SA, often fail to address these unique 
issues adequately. Heroin is the most potentially harmful of the 
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were diagnosed with a comorbid mental illness. Thirty-seven (84%) and 30 (68%) were re-interviewed at the 3- and 9-month follow-up 
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Conclusions. Women with heroin dependence in Johannesburg have high rates of HIV infection and comorbid mental illness and low rates 
of abstinence after inpatient detoxification and psychosocial therapy. Women fared worse than men in many domains of treatment outcome. 
This study builds evidence for the need for gender-sensitive substance rehabilitation facilities in SA.
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substances of abuse.[23] It is therefore critically important to have an 
in-depth understanding of the characteristics of women with heroin 
dependence and to evaluate the outcomes of treatment for those who 
have had the opportunity to access it.
Objectives
To describe the clinical and psychosocial characteristics of women 
entering inpatient rehabilitation for heroin dependence, determine 
the outcomes of treatment 3 and 9 months post rehabilitation, and 
compare these findings with those for male heroin users.
Methods
This was a prospective cohort study of heroin users. Women were 
recruited from a state-funded drug and alcohol rehabilitation centre 
in Gauteng. At the time of data collection, the facility had 20 beds 
allocated to women and ~200 for men. Men were recruited from this 
facility and a second, exclusively male, rehabilitation centre in Soweto. 
A convenience sample of newly admitted heroin users were screened 
for study criteria. Of a total of 317 males and females screened, 8 did 
not fit the inclusion criteria and 5 refused participation. No females 
refused to participate. Four males were excluded at the time of 
baseline psychiatric interviews because they were assessed as actively 
suicidal. The final cohort comprised 44 females and 256 males.
Patients admitted to the facilities were voluntarily seeking 
treatment for substance abuse and most were referred by community-
based social workers. A minority was referred by the courts. Both 
rehabilitation programmes entailed 1 week of inpatient detoxification 
followed by 6 - 8 weeks of psychosocial rehabilitation. The 
rehabilitation programmes consisted primarily of group sessions led 
by social workers and addiction counsellors. Upon completion, most 
patients returned home and were encouraged to see their local social 
workers for follow-up and to attend community-based self-help 
groups such as Narcotics Anonymous. Baseline and follow-up data 
were collected between July 2017 and January 2019. The study was 
approved by the University of the Witwatersrand Human Research 
Ethics Committee (ref. no. M1704100).
We screened clients who reported that nyaope/heroin was their 
primary drug of abuse. In order to be enrolled in the study, 
participants had to have reported using heroin during the months 
prior to admission, be >18 years of age, be willing to provide locator 
information for follow-up to occur, and be able to provide informed 
consent. Participants were assessed during rehabilitation and then 
followed up 3 and 9 months after leaving inpatient rehabilitation. 
Participants were not compensated for their participation, but were 
given ZAR100 for transport if they returned to the research site for 
their follow-up interview. In some cases, the principal investigator 
(PI, NM) did home and/or hangout-spot follow-up visits. Participants 
who were seen at home or hangout spots were not compensated. No 
telephonic interviews were done.
Structured interviews
All baseline and follow-up interviews were conducted face to face 
by the PI, who is a psychiatrist and was not part of the treating team 
at the rehabilitation facilities. Participants did not read or answer 
any of the questionnaires on their own. At baseline, a detailed 
sociodemographic and past substance use questionnaire created 
specifically for the study was administered. The Opiate Treatment 
Index (OTI),[24] which included sections on past-month drug use, 
past-month injecting and sexual practices, social adjustment, past-
month criminal history and general health, was administered at 
baseline and both follow-up occasions. Drug use estimates in the OTI 
are based on the average use episodes of a substance per day. Drug use 
is expressed as a Q score, which describes the frequency of drug use. 
A Q score of 1.00 - 1.99 indicates daily use, and a score >2.00 indicates 
use more than once a day. The social functioning, injecting and sexual 
behaviour, and criminality sections are scored with higher scores 
indicating greater severity or dysfunction.
The Mini International Neuropsychiatric Interview (MINI), version 
7.0.2 for DSM-5,[25] was administered at baseline and both follow-up 
points to determine the presence of the following psychiatric conditions: 
major depressive episode (MDE, past and current), suicidality (current, 
lifetime and future risk), manic and hypomanic episodes, social anxiety 
disorder, obsessive-compulsive disorder, post-traumatic stress disorder 
(PTSD), psychotic disorders, generalised anxiety disorder (GAD) and 
antisocial personality disorder (ASPD). Screening for ASPD was only 
done at the baseline interview.
Urine was collected for a multi-drug urine test (MDUT) for all 
participants who were able to provide a sample. Urine collection was 
unsupervised; however, a research assistant was trained to identify any 
unusual changes in colour, temperature or smell. The MDUT tested for 
the presence of opioids, cocaine, amphetamines, methamphetamine, 
cannabis and benzodiazepines.
Sample size estimation
Sample size estimation for the comparison of female and male 
groups was based on the χ2 test (for categorical variables) with up to 
4 × 2 table size, and the independent-samples t-test (for continuous 
variables); for the detection of a medium effect size (w=0.3 and 
d=0.5, respectively) with 80% power at the 5% level of significance, 
minimum sample sizes of 122 and 128, respectively, are required. 
Sample size calculations were carried out in G*Power.[26]
Data analysis
Comparison of follow-up status (those seen v. those lost to follow-
up (LTFU)) for categorical variables was carried out with the χ2 test. 
Fisher’s exact test was used for 2 × 2 tables or where the requirements 
for the χ2 test could not be met. Continuous variables were assessed 
by the independent-samples t-test. Where the data did not meet 
the assumptions of these tests, a non-parametric alternative, the 
Wilcoxon rank-sum test, was used. Comparison of gender groups at 
enrolment was carried out analogously.
Comparison of binary outcomes at enrolment, 3 months and 
9 months was performed by a generalised estimating equation (GEE) 
model with the outcome as the dependent variable, observation point 
as the independent variable, and participant as the repeated measure. 
Treatment completion, intravenous (IV) drug use, depression and 
PTSD (all at enrolment) were included as covariates. Continuous 
outcomes were compared analogously by a linear mixed model 
(the outcome was log-transformed if necessary, to meet model 
assumptions, followed by back-transformation of model estimates).
Comparison of binary treatment outcomes between men and 
women at 3 months and at 9 months was performed by a GEE 
model with the outcome as the dependent variable, gender as the 
independent variable, and participant as the repeated measure. 
Treatment completion, IV drug use, depression and PTSD (all at 
enrolment) and readmission were included as covariates. Continuous 
outcomes were compared analogously as described above.
Data analysis was carried out using SAS version 9.4 for Windows 
(SAS Institute, USA). A 5% significance level was used.
Results
Characteristics of women at treatment entry
The median (interquartile range (IQR)) age at enrolment was 27 
(22 - 30) years (Table 1). Twenty participants (45%) had a grade 10 
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or 11 qualification, and 16 (36%) had attained a grade 12 or higher 
level of education. Ten participants (23%) had had some form of 
employment during the preceding 6 months, and of these 9 did 
piece work/informal employment. The majority (64%) lived in 
formal accommodation, while 12 (27%) lived in informal housing 
(such as a zozo or shack) and 4 (9%) were living on the streets. 
The majority (66%) had one or more children. There were no 
significant differences between males and females with regard 
to age at the time of study enrolment. Compared with males, a 
higher proportion of females had children (p=0.001) and were 
unemployed (p<0.0001) (Table 1). The median (IQR) age of onset 
of first substance use was 15 (13 - 17) years and the median age 
at first use of heroin was 20 (16 - 23) years. The median duration 
of heroin use was 5 (4 - 9) years. The majority smoked heroin in 
combination with cannabis (73%), while 27% had injected heroin 
during the past month. The median length of stay at rehabilitation 
was 43 (31 - 44) days. Twenty-nine women (66%) completed the 
entire inpatient programme. Fifty-five percent used two or more 
substances. The median Q score for heroin was 8 (4.5 - 10.0) and the 
median Q score for cannabis was 5.3 (0.6 - 9). The most common 
substances used in the past month (other than heroin, cannabis 
and tobacco) were crack cocaine (34%), crystal methamphetamine 
(21%) and methaqualone (18%). Compared with men, there were 
no significant differences in age of first substance use, age of onset 
of heroin use, number of substances used and length of stay in 
inpatient rehabilitation (Table 1).
Excluding ASPD, 33 women (75%) were diagnosed with a mental 
illness (Table 1). The most common were MDE (57%), GAD 
(52%), PTSD (43%) and social anxiety disorder (21%). Thirty-six 
participants (82%) had experienced suicidal feelings during the 
past month and 52% had a lifetime suicide attempt. Thirty-four 
(77%) reported that they had experienced trauma, and 26 (59%) 
had experienced sexual trauma; of these 10 (38%) were sexually 
assaulted during childhood. Sixteen percent reported experiencing 
intimate partner violence. Sixteen women (40%) reported being HIV 
positive. Four women (9%) had never had an HIV test and therefore 
did not know their HIV status. Compared with males, females had 
a significantly higher prevalence of HIV (p=0.006), mental illness 
(p=0.0002) and sexual trauma (p<0.0001) (Table 1).
Twenty-four women (56%) had had two or more sexual partners 
during the past month and 50% had been paid for sex during the 
past month. Seventeen (39%) never or hardly ever used condoms 
with regular sexual partners. With regard to crime, 68% had engaged 
in crime in the past month. The most common types of crime were 
property crime (52%) and dealing drugs (27%). Six (14%) had 
committed fraud during the past month and 5 (11%) reported violent 
crime. When comparing women and men, women had a significantly 
higher number of sexual partners, and a significantly higher number 
were paid for sex. There was no significant difference in use of 
condoms between men and women. Criminality was significantly 
higher in males. Women had significantly poorer social functioning 
scores (p=0.0001) (Table 1).
Comparison between women seen at 3 and 9 months 
and those LTFU
At 3 months, 37 (84%) of participants seen at baseline were 
re-interviewed. Of the 7 LTFU, 4 could not be found as the family 
reported that they had relapsed and were mainly living on the streets. 
At 9 months, 30 participants were re-interviewed and 6 of the 14 
LTFU were reported to be living on the streets.
Table 1. Baseline sample characteristics by gender
Characteristic Women (N=44) Men (N=256) p-value 
Age at study enrolment, median (IQR) 27 (22 - 29) 27 (23 - 30) 0.85
Age at first substance use, median (IQR) 15 (13 - 16.5) 14 (13 - 16) 0.28
Age at onset of heroin use, median (IQR) 19.5 (16 - 23) 19 (17 - 22) 0.79
HLoE (up to grade 11), n (%) 28 (63.6) 182 (71.1) 0.34
Employment status (any past month), n (%) 10 (22.7) 152 (59.4) <0.0001*
OTI drug use scores
Heroin, median (IQR) 8 (4.5 - 10) 7 (4.5 - 10) 0.35
Cannabis, median (IQR) 5.3 (0.6 - 9) 6.5 (2.6 - 10) 0.46
Substance use (any use in past month), n (%)
Alcohol 7 (15.9) 42 (16.4) >0.99
Crystal methamphetamine 9 (20.5) 49 (19.1) 0.84
Crack cocaine 15 (34.1) 63 (24.6) 0.20
Methaqualone 8 (18.2) 47 (18.4) >0.99
Social functioning score, mean (SD) 29.6 (4) 26 (5.8) 0.0001*
Criminality score, mean (SD) 2.8 (3) 4.3 (3.3) 0.0014*
General health score, mean (SD) 23.6 (7) 18.9 (7.2) <0.0001*
HIV-positive, n (%) 16 (40.0) 28 (14.5) 0.0006*
Psychiatric comorbidity, n (%)
Any mental illness (excluding ASPD) 33 (75.0) 115 (44.9) 0.0002*
MDE 25 (56.8) 77 (30.1) 0.001*
GAD 23 (52.3) 55 (21.5) <0.0001*
PTSD 19 (43.2) 34 (13.3) <0.0001*
ASPD 18 (40.9) 139 (54.3) 0.11
Lifetime sexual trauma, n (%) 26 (59.1) 6 (2.3) <0.0001*
IQR = interquartile range; HLoE = highest level of education; OTI = Opiate Treatment Index; SD = standard deviation; ASPD = antisocial personality disorder; MDE = major depressive episode; 
GAD = generalised anxiety disorder; PTSD = post-traumatic stress disorder.
*Significant at p<0.05.
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Owing to the small number of females LTFU, it was not possible 
to analyse differences between those seen and those LTFU. When 
comparing the entire group (males and females), there were a 
few significant differences between those seen and those LTFU. 
At 3-month follow-up, a higher proportion of participants who 
were followed up successfully had been living in formal housing at 
enrolment, compared with those LTFU (p=0.042). At the 9-month 
follow-up, those who were followed up successfully had a higher 
median duration of heroin use (7 v. 6 years; p=0.033), a lower 
proportion of cannabis without heroin users (p=0.048), a lower 
proportion of mental illness (p=0.047), a higher proportion of 
methaqualone users (p=0.0098) and a higher proportion living in 
formal housing (p<0.0001).
Treatment history for women between index 
rehabilitation and 9 months
Of the participants, 19 (51%) reported attending Narcotics Anony-
mous peer-support groups at 3 months and 6 (20%) at 9 months. At 
9 months, 2 participants had received treatment at a halfway house. 
From enrolment to 9 months, 2 participants reported receiving 
psychotropic medication and 1 received individual therapy sessions 
after discharge from the inpatient facility. Three women reported 
falling pregnant during the study period. Specific details of the 
obstetric outcomes were not collected for this study. None of the 
participants who were pregnant received opioid agonist maintenance 
treatment (OAMT).
Treatment outcomes for women at 3 and 9 months
At 3 months, 6 participants (16%) were abstinent from all substances 
(excluding tobacco) and 2 (7%) were abstinent from all substances at 
9 months. Thirteen (35%) were abstinent from heroin at 3  months 
and 6 (20%) at 9 months (Table 2). Heroin and cannabis abstinence 
decreased significantly from 3 to 9 months. Alcohol abstinence 
decreased significantly from enrolment to 3 months (84% at 
enrolment v. 59% at 9 months; p=0.017). There was no significant 
improvement in the prevalence of any mental illness from treatment 
entry to 3 and 9 months post treatment. There was significant 
improvement in mean social functioning scores from treatment entry 
to 3 months, but no significant improvement thereafter. There was a 
significant deterioration in general health scores from 3 to 9 months 
(p<0.0001).
Comparison of treatment outcomes between  
men and women
Total abstinence was significantly higher in women at 3 months 
(p=0.008) (Table 3). There were no significant differences between 
men and women in total abstinence at 9 months and heroin abstinence 
at 3 and 9 months. Past-month alcohol use was significantly higher 
in men at 3 and 9 months. At 9 months, women scored significantly 
worse than men in the areas of social functioning, risky sexual 
behaviour and general health. There were no significant differences 
in criminality at 3 and 9 months. Compared with men, a significantly 
higher proportion of women felt that their partner’s use of substances 
contributed to their heroin relapse (74% v. 20%; p<0.0001).
Discussion
We have presented results of the first prospective study of female 
heroin users in SA. The data highlight high levels of trauma, mental 
illness and HIV in women with heroin dependence and expose 
significant gaps in treatment services. The study also draws attention 
to differences between men and women with heroin use disorder, 
and builds evidence for a need for gender-sensitive treatment 
services. The following discussion will provide a broader context and 
interpretation of the results while also making suggestions on the 
way forward.
During the recruitment period, we attempted to enrol as many 
female participants as possible, but the study concluded with a sample 
size of 44 women v. 256 men. The gender bias in the overall sample 
probably reflects the low number of women entering treatment 
facilities owing to the various barriers mentioned at the beginning 
of the article.[14] There were considerably fewer beds allocated 
to women, supposedly as a result of lower demand for inpatient 
female admissions. When comparing baseline demographics with 
those of men, there were no significant differences in age at study 
enrolment, age at first substance use or age at onset of heroin 
use. However, despite similar length of drug use to men, women 
suffered more harms associated with heroin use. This is evidenced 
in our data by higher prevalences of unemployment, psychiatric 
Table 2. Treatment outcomes for women†
Outcome Enrolment (N=44) 3 months (N=37) 9 months (N=30)
p-value
En - 3 mo En - 9 mo 3 - 9 mo
Past-month abstinence, n (%)
Total abstinence (excluding tobacco) 0 6 (16.2) 2 (6.7) 0.26
Heroin 0 13 (35.1) 6 (20.0) 0.023*
Cannabis 6 (13.6) 12 (32.4) 5 (16.7) 0.023* 0.89 0.043*
Alcohol 37 (84.1) 22 (59.4) 23 (76.7) 0.017* 0.60 0.29
Crystal methamphetamine 35 (79.6) 30 (81.1) 24 (80.0) 0.98 0.99 0.99
Crack cocaine 29 (65.9) 30 (81.1) 20 (66.7) 0.31 0.99 0.21
Methaqualone 36 (81.8) 34 (91.9) 24 (80.0) 0.36 0.99 0.34
Any mental illness (excluding ASPD) 33 (75.0) 21 (56.8) 18 (60.0) 0.15 0.23 0.96
Criminality score, mean (95% CI) 2.4 (1.6 - 3.6) 0.7 (0.4 - 1.2) 0.7 (0.4 - 1.2) <0.0001* <0.0001* 0.055
Sexual behaviour score, mean (95% CI) 6.8 (5.5 - 8.2) 5.5 (3.9 - 7.2) 5.3 (4.0 - 6.7) 0.14 0.021 0.96
Social functioning score, mean (95% CI) 29.2 (27.8 - 30.6) 24.5 (22.1 - 26.9) 27.3 (25.1 - 29.5) 0.0004* 0.22 0.059
General health score, mean (95% CI) 23.4 (21.4 - 25.3) 13.5 (11.0 - 16.1) 19.6 (17.2 - 21.9) <0.0001* 0.045 <0.0001*
En = enrolment; ASPD = antisocial personality disorder; CI = confidence interval; IV = intravenous; MDE = major depressive episode; PTSD = post-traumatic stress disorder.
*Significant at p<0.05.
†Where sample size was adequate, the model controlled for the following covariates: treatment non-completers, IV users, diagnosis of MDE at treatment entry, diagnosis of PTSD at treatment 
entry, treatment readmission.
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comorbidities and HIV and poorer social functioning and general 
health scores in women. Our findings are therefore in keeping with 
the literature describing the concept of telescoping, whereby women 
with substance dependence display higher levels of functional 
impairment in a similar or shorter length of time.[5,8,27,28]
On closer examination of the comorbidities present in women, 
we found that the overwhelming majority of women (75%) were 
diagnosed with a psychiatric comorbidity. The most common were 
MDE, GAD and PTSD. In keeping with data from developed 
countries, almost 80% reported a lifetime experience of trauma 
(although not all fulfilled criteria for PTSD), and the majority of 
the traumas reported were sexual traumas and intimate partner 
violence. [29] There are limited data assessing psychiatric comorbidities 
in women with heroin dependence. In a sample of 49 women with 
heroin use disorder in Spain, 36.7% had a mood disorder, 4% had 
GAD and 6% had PTSD.[30] In the USA, 29.7% of women with 
substance use disorder were also diagnosed with a mood disorder. [5] 
In our sample, the prevalence of MDE, GAD and PTSD was markedly 
higher than in data from developed countries. It may be that the 
low number of women in our sample receiving medication for 
psychiatric comorbidities contributed to the higher occurrence of 
mental illnesses.
Between index rehabilitation and 9-month follow-up, the majority 
of women did not consult with psychiatrists or psychologists or 
receive psychotropic medication. As a result, there were no significant 
changes in the prevalence of mental illness over the course of the 
study period. We recommend that all women attending substance 
rehabilitation services also have access to psychiatric care. This could 
be achieved by including psychiatrists as members of the treating 
team in rehabilitation facilities and by improving communication 
between rehabilitation and low-threshold community-based 
psychiatric services.
In our sample, 12 women (27%) were injecting heroin. Fifty percent 
engaged in sex work and almost 40% reported rarely using condoms 
with their regular partners. Forty percent were HIV-positive. The 
increasing number of women affected by substance abuse, violence 
and HIV/AIDS is referred to as the SAVA syndemic in the USA. [11] 
The women in our study are likely to represent one of the most 
vulnerable groups of women in SA. Sex work in female injecting and 
non-injecting heroin users is often a means of supporting their own 
and their partner’s habit.[27] Our study also found that 74% of women 
were negatively influenced by having a partner who used heroin. This 
is in keeping with previous studies which report that women are more 
likely than men to be introduced to injecting heroin by their sexual 
partners and that women are particularly influenced by their sexual 
partners’ injecting behaviour.[31,32]
Importantly, women who were pregnant during the study period 
continued to use heroin and did not have access to OAMT or 
specialised services that cater to the needs of pregnant women 
with heroin use disorder. World Health Organization guidelines for 
substance abuse in pregnant women advocate the use of methadone 
as maintenance therapy during pregnancy,[33] and a recently published 
systematic review by leading SA researchers suggested the same.[34] 
Gender-specific and gender-sensitive treatment options for women 
with substance use disorder have been evaluated in developed 
countries.[28] Data from the present study suggest that the same is 
needed in SA.
We found that levels of violent trauma, mental illness, social 
dysfunction and physical ill health at treatment entry were 
substantially higher in women than in men. At 9 months, men and 
women had similar levels of drug use and criminality, but women 
fared worse in terms of general health, social functioning and high-
risk sexual behaviour. Overall treatment outcomes were therefore 
poorer in women. Women-only treatment services and treatment 
Table 3. Comparison of treatment outcomes by gender†
Outcome
Men, 3 months 
(N=215)
Women, 3 months 
(N=37)
Men, 9 months 
(N=195)
Women, 9 months 
(N=30)
p-value
Between 
groups  
(3 months)
Between 
groups  
(9 months)
Past-month abstinence, n (%)
 Total abstinence  
(excluding tobacco)
10 (4.7) 6 (16.2) 9 (4.6) 2 (6.7) 0.008* 0.64
Heroin 81 (37.7) 13 (35.1) 52 (26.7) 6 (20.0) 0.57 0.29
Cannabis 56 (26) 12 (32.4) 35 (17.9) 5 (16.7) 0.14 0.84
Alcohol 91 (42.3) 22 (59.5) 99 (50.8) 23 (76.7) 0.008* 0.001*
Crystal methamphetamine 163 (75.8) 30 (81.1) 155 (79.5) 24 (80) 0.98 0.91
Crack cocaine 179 (83.3) 30 (81.1) 154 (79.0) 20 (66.7) 0.81 0.14
Methaqualone 175 (81.4) 34 (91.9) 154 (79.0) 24 (80.0) 0.26 0.41
Any mental illness  
(excluding ASPD), n (%)
82 (38.1) 21 (56.8) 66 (33.8) 18 (60.0) 0.53 0.07
Criminality score, mean  
(95% CI)
0.3 (0.0 - 4.8) 1.5 (1.1 - 2.1) 2.4 (1.8 - 3.2_ 0.9 (0.3 - 3.2) 0.26 0.15
Sexual behaviour score,  
mean (95% CI)
4.1 (3.1 - 5.5) 8.4 (6.0 - 11.8) 3.2 (2.4 - 4.2) 5.4 (3.9 - 7.4) <0.0001* 0.0003*
Social functioning score,  
mean (95% CI)
22.5 (21.7 - 23.2) 25.0 (22.6 - 27.4) 22.4 (21.6 - 23.3) 27.8 (25.4 - 30.2) 0.002* <0.0001*
General health score,  
mean (95% CI)
14.5 (11.5 - 18.4) 17.4 (13.0 - 23.3) 14.5 (12.2 - 17.2) 20.2 (16.2 - 25.1) 0.14 0.001*
ASPD = antisocial personality disorder; CI = confidence interval; IV = intravenous; MDE = major depressive episode; PTSD = post-traumatic stress disorder.
*Significant at p<0.05.
†The model controlled for the following covariates: treatment non-completers, IV users, diagnosis of MDE at treatment entry, diagnosis of PTSD at treatment entry, treatment readmission.
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services that cater to women with children and women with the triple 
diagnosis of substance use disorder, mental illness and HIV should 
be considered in SA. Data also show that women who use drugs 
experience higher levels of discrimination and stigma than their 
male counterparts.[27] Health and social services should therefore 
train all service providers adequately, and facilities should deliver a 
supportive, culturally sensitive and non-judgmental environment.
Study limitations
When interpreting the study results, there are some limitations 
to consider. We had a small sample of women compared with 
men. Owing to the challenges of entering treatment for women, 
women in this study may be representative of those with more 
severe dependence compared with a wider range of men entering 
treatment. These factors may introduce a gender bias when 
comparing data between men and women. While the small sample 
size of women compared with men poses a limitation to this 
study, the overall sample of 300 is in excess of the minimum 
sample size requirement, insuring against additional requirements 
arising from group imbalance. The generalisability of the study 
is also limited by the fact that women were recruited from one 
inpatient rehabilitation facility in Gauteng. Future studies should 
include a larger sample of women from more treatment sites. An 
additional consideration would be to include a control group of 
women not entering treatment. A control group may enable more 
accurate evaluation of the impact of detoxification and psychosocial 
rehabilitation in women with heroin dependence.
Conclusions
The cohort of women in this study represents a highly stigmatised, 
vulnerable group who require more representation in health policy. 
Our failure to meet the needs of these women will result in 
even higher levels of morbidity and mortality for them and for 
their children, and may exacerbate intergenerational trauma. Civil 
society, policymakers, researchers and healthcare providers should 
collaborate to provide gender-specific and gender-sensitive treatment 
for women with heroin dependence in SA.
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